(S (NP (NP (NNS People)) (PP (IN with) (NP (NML (NN Type) (CD 1)) (NN diabetes) (PRN (-LRB- -LRB-) (NP (NN T1D)) (-RRB- -RRB-))))) (VP (VBP require) (NP (NP (JJ regular) (JJ exogenous) (NN infusion)) (PP (IN of) (NP (NN insulin)))) (S (VP (TO to) (VP (VB maintain) (NP (PRP$ their) (NML (NN blood) (NN glucose)) (NN concentration)) (PP (IN in) (NP (DT a) (ADJP (RB therapeutically) (JJ adequate)) (NN target) (NN range))))))) (. .))
(S (SBAR (IN Although) (S (NP (DT the) (NML (NML (JJ artificial) (NN pancreas)) (CC and) (NML (JJ continuous) (NN glucose))) (NN monitoring)) (VP (VBP have) (VP (VBN been) (VP (VBN proven) (S (VP (TO to) (VP (VB be) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG achieving) (NP (NML (JJ closed) (HYPH -) (NN loop)) (NN control)))))))))))))) (, ,) (NP (JJ significant) (NNS challenges)) (ADVP (RB still)) (VP (VBP remain) (ADJP (JJ due) (PP (IN to) (NP (NP (DT the) (JJ high) (NN complexity)) (PP (IN of) (NP (NN glucose) (NNS dynamics) (CC and) (NNS limitations)))))) (PP (IN in) (NP (DT the) (NN technology)))) (. .))
(S (PP (IN In) (NP (DT this) (NN work))) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (DT a) (JJ novel) (JJ deep) (NN reinforcement)) (S (VP (VBG learning) (NP (NN model)) (PP (IN for) (NP (NML (NML (JJ single) (HYPH -) (NN hormone) (PRN (-LRB- -LRB-) (NP (NN insulin)) (-RRB- -RRB-))) (CC and) (NML (JJ dual) (HYPH -) (NN hormone) (PRN (-LRB- -LRB-) (NP (NN insulin) (CC and) (NN glucagon)) (-RRB- -RRB-)))) (NN delivery)))))) (. .))
(S (PP (IN In) (ADJP (JJ particular))) (, ,) (NP (DT the) (NN delivery) (NNS strategies)) (VP (VBP are) (VP (VBN developed) (PP (IN by) (NP (JJ double) (NML (NN Q) (HYPH -) (NN learning)))) (PP (IN with) (NP (ADJP (VBN dilated) (JJ recurrent)) (JJ neural) (NNS networks))))) (. .))
(S (PP (IN For) (S (VP (VBG designing) (CC and) (VBG testing) (NP (NP (NNS purposes)) (, ,) (NP (NP (DT the) (NNP FDA)) (HYPH -) (VP (VBN accepted) (NP (NN UVA) (HYPH /) (NN Padova)))))))) (NP (NML (NN Type) (CD 1)) (NN simulator)) (VP (VBD was) (VP (VBN employed))) (. .))
(S (ADVP (RB First)) (, ,) (NP (PRP we)) (VP (VBD performed) (S (NP (NML (RB long) (HYPH -) (NN term)) (VBN generalized) (NN training)) (VP (TO to) (VP (VB obtain) (NP (DT a) (NN population) (NN model)))))) (. .))
(S (ADVP (RB Then)) (, ,) (NP (DT this) (NN model)) (VP (VBD was) (ADJP (VBN personalized) (PP (IN with) (NP (NP (DT a) (JJ small) (NN data) (HYPH -) (NN set)) (PP (IN of) (NP (ADJP (JJ subject) (HYPH -) (JJ specific)) (NNS data))))))) (. .))
(S (NP (ADJP (FW In) (FW silico)) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (DT the) (UCP (ADJP (JJ single)) (CC and) (NML (JJ dual) (HYPH -) (NN hormone))) (NN delivery) (NNS strategies)) (VP (VBP achieve) (NP (JJ good) (NN glucose) (NN control)) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN to) (NP (NP (DT a) (JJ standard) (NML (JJ basal) (HYPH -) (NN bolus)) (NN therapy)) (PP (IN with) (NP (NML (JJ low) (HYPH -) (NN glucose)) (NN insulin) (NN suspension)))))))))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ adolescent) (NN cohort) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (SYM =) (NP (CD 10)))) (-RRB- -RRB-)))) (, ,) (NP (NP (NN percentage) (NN time)) (PP (IN in) (NP (NN target) (NN range)))) (VP (VBN improved) (PP (IN from) (NP (QP (CD 55.5) (NN %) (IN to) (CD 65.9) (NN %)))) (PP (IN with) (NP (NP (NML (JJ single) (HYPH -) (NN hormone)) (NN control)) (, ,) (CC and) (NP (QP (IN to) (CD 78.8)) (NN %)))) (PP (IN with) (NP (NML (JJ dual) (HYPH -) (NN hormone)) (NN control)))) (. .))
(S (PP (IN In) (NP (DT all) (NNS scenarios))) (, ,) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NN hypoglycemia)))) (VP (VBD was) (VP (VBN observed))) (. .))
(S (NP (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ deep) (NN reinforcement) (NN learning)))) (VP (VBZ is) (NP (NP (DT a) (JJ viable) (NN approach)) (PP (IN for) (NP (NP (NML (JJ closed) (HYPH -) (NN loop)) (NN glucose) (NN control)) (PP (IN in) (NP (NN T1D)))))))))) (. .))
